Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pelthos Therapeutics (NYSE American: PTHS) announced that its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on August 4, 2026 may vote at the meeting.
Pelthos expects to file its Notice of Annual Meeting and proxy statement in early August 2026. Because the 2026 meeting date is more than 30 days from the 2025 meeting anniversary, stockholder proposals under Rule 14a-8 must be received by August 3, 2026 for inclusion in the proxy materials.
Details
News Market Reaction – PTHS
On Jul 27, the first trading day after this news, PTHS closed 6.44% above the previous close. Argus tracked a peak move of +6.1% during that session. Our momentum scanner recorded 9 alerts for this stock that day. That session’s volume was 1.9x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jul 27 session.
Key Figures
- Annual Meeting Date
- September 29, 2026 at 9:00 a.m. Eastern Time
- 2026 Annual Meeting of Stockholders
- Record Date
- August 4, 2026
- Stockholder voting eligibility
- Meeting Date Change
- More than 30 days
- Change from the anniversary of the 2025 Annual Meeting
- Proposal Deadline
- August 3, 2026
- Rule 14a-8 stockholder proposals
Historical Context
-
Russell index additions became effective following the 2026 Russell US Indexes reconstitution.
-
CEO presentation and investor meetings were scheduled at Jefferies healthcare conference.
-
Q1 revenue growth and narrower net loss highlighted ZELSUVMI commercialization.
-
Company scheduled first-quarter financial results and conference call for May 14, 2026.
-
CEO scheduled one-on-one investor meetings at Piper Sandler biopharma symposium.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
rule 14a-8 regulatory
proxy statement regulatory
stockholders of record regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of Annual Meeting and proxy statement in early August 2026.
The date of the 2026 Annual Meeting represents a change of more than 30 days from the anniversary of the Company’s 2025 Annual Meeting. Given the adjustment, stockholder proposals pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must be received in writing by the Company before the close of business on August 3, 2026 to be considered for inclusion in the Company’s proxy materials for the 2026 Annual Meeting.
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel,
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.